Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 1Phase 2 1

Status

Completed 5

Sponsor Class

OTHER 5INDUSTRY 3NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 96Lymphoid 56Myeloid 37Gastrointestinal 16CNS 14Thoracic 13Breast 13Genitourinary 11Sarcoma 9Other solid neoplasm 8Plasma cell 6Tumor-Agnostic 5Dermatologic 5Head & Neck 4Gynecologic 3Classical hematology 1

Conditions

Neoplasm Metastasis 4Neoplasms 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Dasatinib × Tumor-Agnostic × Clear all
NCT01744652 2023-06-07

Dasatinib and Crizotinib in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
62 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01015222 2022-11-23

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
122 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01636908 2021-04-15

ICK

Amsterdam UMC, location VUmc

Phase NA Completed
43 enrolled
Tumor-Agnostic

Neoplasms

NCT00717704 2020-08-05

Solid Tumors Using Ixabepilone and Dasatinib

Medstar Health Research Institute

Phase 1 Completed
19 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02142036 2019-03-13

MetAction

Oslo University Hospital

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡